BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/28/2019 10:38:52 AM | Browse: 143 | Download: 129
Publication Name World Journal of Gastroenterology
Manuscript ID 51278
Country/Territory China
2019-09-06 03:58
Peer-Review Started
2019-09-06 03:58
To Make the First Decision
2019-10-14 09:39
Return for Revision
2019-10-16 01:07
2019-11-08 12:05
Second Decision
2019-11-12 11:01
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-11-13 01:47
Articles in Press
2019-11-13 01:47
Publication Fee Transferred
Edit the Manuscript by Language Editor
2019-11-17 13:38
Typeset the Manuscript
2019-11-27 12:14
Publish the Manuscript Online
2019-11-28 10:38
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Observational Study
Article Title Real life efficacy and safety of direct-acting antiviral therapy for treatment of hepatitis C-infected patients with genotypes 1, 2 and 3 in northwest China
Manuscript Source Unsolicited Manuscript
All Author List Ying Yang, Feng-Ping Wu, Wen-Jun Wang, Juan-Juan Shi, Ya-Ping Li, Xin Zhang and Shuang-Suo Dang
Author(s) ORCID Number
Ying Yang http://orcid.org/0000-0002-8718-0993
Feng-Ping Wu http://orcid.org/0000-0002-4572-3873
Wen-Jun Wang http://orcid.org/0000-0001-9861-1763
Juan-Juan Shi http://orcid.org/0000-0002-5626-9821
Ya-Ping Li http://orcid.org/0000-0002-0900-5559
Xin Zhang http://orcid.org/0000-0002-5966-0471
Shuang-Suo Dang http://orcid.org/0000-0003-0918-9535
Funding Agency and Grant Number
Corresponding author Shuang-Suo Dang, MD, PhD, Academic Fellow, Academic Research, Doctor, Professor, Infectious Disease, the Second Affiliated hospital of Xi'An Jiaotong University, Department of Infectious Disease, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'An, Shannxi Province, China. dang212@126.com, Xi'An 710004, Shaanxi, China. dang212@126.com
Keywords Hepatitis C; Direct-acting antiviral agents; Efficacy; Safety; Drug-drug interactions; Real-life experience
Core Tip Direct-acting antiviral agents (DAAs) based regimens are currently the preferred treatment for hepatitis C. However, there is not enough data reporting the results of real-world research, especially in countries such as China where DAAs have only been approved for using in recent years. We found that there was no significant difference in sustained virological responses (SVR) between patients with different genotypes and liver statuses. Patients with lower alanine aminotransferase levels at baseline who achieved end of treatment response were more likely to achieve SVR at post-treatment week 12. Also, we found two cases of special adverse events. One case involved facial and bilateral lower extremity edemas, which was due to drug-drug interactions and the other case showed an interesting change in lipid levels while the patient was on medication.
Publish Date 2019-11-28 10:38
Citation Yang Y, Wu FP, Wang WJ, Shi JJ, Li YP, Zhang X, Dang SS. Real life efficacy and safety of direct-acting antiviral therapy for treatment of hepatitis C-infected patients with genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019; 25(44): 6551-6560
Url https://www.wjgnet.com/1007-9327/full/v25/i44/6551.htm
DOI https://dx.doi.org/10.3748/wjg.v25.i44.6551
Full Article (PDF) WJG-25-6551.pdf
Full Article (Word) WJG-25-6551.docx
Manuscript File 51278-Review_Edited.docx
Answering Reviewers 51278-Answering reviewers.pdf
Audio Core Tip 51278-Audio core tip.mp3
Biostatistics Review Certificate 51278-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form 51278-Conflict-of-interest statement.pdf
Copyright License Agreement 51278-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s) 51278-Informed consent statement.pdf
Institutional Review Board Approval Form or Document 51278-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 51278-Language certificate.pdf
Peer-review Report 51278-Peer-review(s).pdf
Scientific Misconduct Check 51278-Bing-Tang JZ-2.png
Scientific Misconduct Check 51278-Scientific misconduct check.pdf
Scientific Editor Work List 51278-Scientific editor work list.pdf